DEBIOPHARM AND ASPEN TEAM UP TO LAUNCH PROSTATE CANCER MEDICINE TRELSTAR® IN SOUTH AFRICA


LAUSANNE, Switzerland and DURBAN, South Africa, February 1, 2022 /PRNewswire/ — Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and aspena multinational pharmaceutical company based in South Africa, today announced its partnership to launch Trelstar® (triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone-dependent prostate cancer. (Trelstar®a synthetic analogue of GnRH (Gonadotropin Releasing Hormone) developed by Debiopharm, will be marketed by aspen in South Africa.

In 2020, nearly 14,000 South African men were newly diagnosed with prostate cancer1 with an average of 5 men dying from the disease each day.2 In fact, 1 in 23 South African men will develop prostate cancer in their lifetime.2 Trelstar works by reducing levels of testosterone, a hormone essential for prostate cancer growth. Testosterone deprivation stops the growth of hormone-dependent prostate cancer, alleviates pain and improves patients’ quality of life.

We are really excited about entering into this new alliance with aspena well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could help patients with prostate cancer in this region. Fabrice Paradies, Senior Director, Business Development and Global Commercial Alliances, Debiopharm.

Aspen Pharmacare is delighted to be able to offer a world-class oncology product in the treatment of prostate cancer and we are privileged to partner with Debiopharm to bring Trelstar to market.® in the South African market. We are confident that this product will add significant benefits to the treatment of prostate cancer. Neel Andhee-Shah, Manager: New Product Development, Aspen Pharmacare.

About Trelstar® (Triptorelin)
Trelstar® (Triptorelin) is an agonist analog of natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained release formulations (1, 3 and 6 months) of Triptorelin Pamoate. First registration in France in 1986, Triptorelin is currently marketed in more than 80 countries by Debiopharm’s selected partners and is the market leader in many territories around the world.

On aspen
Based at Durban, South Africa, aspen is a partner of choice as it is a global branded and specialty pharmaceutical multinational with presence in both emerging and developed markets. aspen improves the health of patients in more than 150 countries through its affordable and high-quality medicines. Active at each stage of the value chain, aspen is uniquely diverse in geography, products and manufacturing capacity. The Group’s main business segments are manufacturing and commercial pharmaceuticals, comprising regional brands and sterile flagship brands. For more information, please visit https://www.aspenpharma.com/.

Debiopharm’s commitment to patients
Debiopharm develops innovative therapies that target important unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify compounds and technologies with high potential for out-licensing, clinically demonstrate their safety and efficacy, and then select great pharmaceutical commercialization partners for maximize patient access globally.

Visit us www.debiopharm.com/
Follow us @DebiopharmNews on http://twitter.com/DebiopharmNews

Contact Debiopharm
Dawn Bonine – Responsible for the communication
[email protected]
Tel: +41 (0)21 321 01 11

The references
1. Globocan 2020; https://gco.iarc.fr/today/data/factsheets/populations/913-southern-africa-fact-sheets.pdf
2. https://mensfoundation.co.za/mens-health/prostate-cancer/

SOURCE Debiopharm International SA

Previous Vancouver startup gets $40 million to marry the power of Cryo-EM and AI
Next Laughlin to introduce PBM reverse auction legislation